MedAI Verdict
Radiology

AI Radiology

icometrix logo

icometrix

by icometrix NV  ·  founded 2011  ·  BE

Last verified

FDA-cleared icobrain AI quantifies brain structures and lesions on MRI and CT and tracks changes over time.

Visit icometrix (opens in new tab)Read our methodology

At a glance

Pricing
No public price.
HIPAA
Not disclosed
SOC 2
Not disclosed
EHRs
—
Founded
2011
HQ
BE
On this page

Independent score  ·  By our public rubric

68/100Top-ranked

Editorial rating 4.5 / 5

How it’s computed →
  • Regulatory & Compliance
    18/28

    FDA cleared (6 K-numbers on record)

  • Clinical Integration
    0/6.6

    No EHR integrations listed

  • Evidence Strength
    22.1/26

    5 peer-reviewed papers

  • Vendor & Market
    14.4/18

    Mid-tier funding and adoption

  • Sentiment & Transparency
    2.5/5

    Pricing on request, no public amounts

▸ Show all 11 dimensions

Regulatory & Compliance

  • FDA clearance18/18

    FDA cleared (6 K-numbers on record)

  • HIPAA / SOC2 / BAA0/10

    No public HIPAA/SOC2/BAA attestation

Clinical Integration

  • EHR integrations (count)0/4

    No EHR integrations listed

  • Top-3 EHR coverage (Epic / Oracle / Athena)0/2

    None of the top-3 EHRs covered

Evidence Strength

  • Peer-reviewed papers18/18

    5 peer-reviewed papers

  • RCT / meta-analysis / systematic review4/8

    1 observational study (no RCT)

Vendor & Market

  • Funding & adoption signal8/12

    Mid-tier funding and adoption

  • Years in market6/6

    Founded 2011 (15 years)

Sentiment & Transparency

  • Pricing transparency3/5

    Pricing on request, no public amounts

Scored November 2, 2026 · Public scoring method v1.2.0

FDA-cleared icobrain AI quantifies brain structures and lesions on MRI and CT and tracks changes over time.

No public price.

Evidence record

FDA decisions
Show 1 more
Peer-reviewed

5 studies on PubMed: 4 other, 1 observational, published 2023 to 2026. Read the literature summary

Verification
  • Score computed November 2, 2026, method 1.2.0
  • Review written November 2, 2026
Cite this record

MedAI Verdict, icometrix record, https://medaiverdict.com/tools/icometrix, version November 2, 2026

Change history
View every change to this record

Bottom line

icometrix NV of Leuven, Belgium sells icobrain, a family of modules that quantify brain structures and lesions on MRI and compare scans over time, plus CT modules for perfusion and trauma. GE HealthCare announced an agreement to acquire the company in September 2025 on undisclosed terms. The icometrix website banner now reads "icometrix is now a GE HealthCare company", and the closing is not confirmed. FDA's records list six icobrain clearances from August 2016 to November 2024. Neurology and memory clinics tracking multiple sclerosis, dementia or amyloid therapy patients fit the product. A hospital that requires a scanner independent vendor has no answer yet, since GE's release describes distribution on all vendor MRI systems and integration with GE MR.

What does icobrain cover?

The modules are named ms, dm, aria, tbi and ctp, and the vendor's pages cover multiple sclerosis, dementia and Alzheimer's, epilepsy, stroke, traumatic brain injury and ARIA. The core is brain volumetry and lesion quantification with longitudinal comparison on MRI.

The clearance that matters most to a current buyer is icobrain aria (K240712, November 2024), which the vendor says "detects parenchymal vasogenic edema, gyral swelling and sulcal effusion" for ARIA-E and ARIA-H in patients on amyloid targeting therapy. The vendor calls it the only FDA-cleared CADe/CADx solution in neuroradiology. For multiple sclerosis the vendor claims 150% more disease activity detected, 35% more reading consistency and 2.5 times faster detection of treatment failure.

What does independent evidence show?

PubMed papers on icobrain are mostly research cohorts that use it as a measuring tool, and a minority validate it. The 2024 JAMA Network Open reader study of ARIA detection (PMID 38345816) was written by Sima and colleagues, who are icometrix-linked per the vendor's own page. The vendor attributes its aria figures of 87% sensitivity for ARIA-E and 79% for ARIA-H, with specificity above 80%, to Sima 2024. A 2026 Diagnostics paper (PMID 42587620) compares four commercial brain volumetry products head to head. A 2025 Frontiers in Neurology study of real world volumetry in multiple sclerosis stresses that results depend on methodological consistency across scanners and sequences.

What about the GE deal and buying?

icometrix was founded in 2011 as a spin off of two Belgian universities and hospitals, with Wim Van Hecke as CEO. GE's release intends distribution on all vendor MRI systems and integration with GE MR, and lists GE's own MIMneuro among its neuro tools. Whether icobrain stays vendor neutral is an open question.

The site routes buyers to a "Speak with an expert" contact page and shows no public price. The vendor points to AMA CPT III codes 0865T and 0866T for reimbursement.

The verdict

icobrain gives neurology services that follow multiple sclerosis or amyloid therapy patients volumetry and ARIA detection on MRI. Scanner independence is the open question after the GE announcement. GE's release names its own MIMneuro among its neuro tools.

Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.

What it costs

All tiers are custom-quoted. The vendor does not publish per-provider list pricing.

TierMonthlyAnnualNotes
EnterpriseNot statedNot statedNo public price.

Source: vendor pricing page. Last checked November 2, 2026.

What deploys cleanly

Carries FDA 510(k), CE per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.

Who builds it

icometrix (icometrix NV) was founded in 2011 in BE, putting it 15 years into market.

What the literature says

5 peer-reviewed studies indexed on PubMed evaluate icometrix in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.

Lecanemab in practice: AI-derived MRI predictors of benefit and Amyloid Related Imaging Abnormalities (ARIA). (opens in new tab)
Bregman N, de Barros NP, Nathan T, et al.· Alzheimers Res Ther· 2026
Lecanemab, a monoclonal antibody targeting amyloid beta, has demonstrated meaningful clinical benefits in early Alzheimer's disease (AD), yet real-world data is needed to optimize patient selection and enhance safety monitoring, particularly with respect to amyloid-related imaging abnormalities (ARIA). Integration of quantitative and AI-derived MRI biomarkers may improve risk stratification and prediction of clinical trajectory. We conducted a retrospective real-world study of eighty-two patients with biomarker-confirmed early AD who initiated lecanemab at Tel Aviv Sourasky Medical Center bet…
Uncovering heterogeneous cognitive trajectories in relapsing-remitting multiple sclerosis: a longitudinal study. (opens in new tab)
London F, De Haan A, Benyahia Z, et al.· Acta Neurol Belg· 2025
Cognitive impairment (CI) frequently occurs in relapsing-remitting multiple sclerosis (RRMS) and is assumed to be irreversible. Recent longitudinal studies highlighted the heterogeneity of CI in RRMS, challenging the traditional view of inevitable progression. Longitudinal studies exploring the baseline determinants of future cognitive decline are limited, and none yet explored the predictive value of patient-reported outcome measures (PROMs). To explore the evolutionary patterns of cognitive status in a cohort of RRMS patients initiating a new disease modifying treatment, and to determine wh…
Quantifying White Matter Hyperintensities: Automated Volumetry Compared with Visual Grading Scales. (opens in new tab)
Titovs A, Šilovs A, Kaļva K, et al.· Medicina (Kaunas)· 2025
White matter hyperintensities (WMHs) on brain magnetic resonance imaging (MRI) are linked to cognitive decline, but clinical assessment still relies mainly on visual grading (Fazekas), which is coarse and rater-dependent. We described the lesion volume of WMHs and the association of the anatomical distribution with the severity of cognitive impairment using automated lesion analysis. In addition, we evaluated whether automated volumetric quantification is more strongly associated with cognitive performance than visual grading.In a retrospective cross-sectional study, forty-one adults referred…
Neuroimaging characteristics may aid in diagnosis, subtyping, and prognosis in autoimmune encephalitis. (opens in new tab)
Broadley J, Wesselingh R, Beech P, et al.· Neurol Sci· 2023Observational
To examine the utility of neuroimaging characteristics as biomarkers of prognosis in seropositive autoimmune encephalitis (AE). In this multi-center study, we retrospectively analyzed 66 cases of seropositive AE. The MRI and PET imaging was assessed by independent visual inspection. Whole brain and regional volumes were imputed by IcoMetrix, an automated volumetric assessment package. The modified Rankin Scale (mRS) was utilized to assess the patients' follow-up disability. Other outcomes were mortality, first line treatment failure, medial temporal lobe (MTL) atrophy, and clinical relapse. U…
Cognitive trajectories in relapsing-remitting multiple sclerosis: Evidence of multiple evolutionary trends. (opens in new tab)
London F, De Haan A, Benyahia Z, et al.· Mult Scler Relat Disord· 2023
Cognitive impairment (CI) frequently occurs in multiple sclerosis (MS) and is assumed to increase over time. However, recent studies have suggested that the evolution of cognitive status in patients with MS may be more heterogeneous than expected. Predicting CI remains also challenging, and longitudinal studies exploring the baseline determinants of cognitive performances are limited. No studies have explored the predictive value of patient-reported outcome measures (PROMs) regarding future CI. To explore the evolutionary patterns of cognitive status in a cohort of RRMS patients initiating a…

See all on PubMed (opens in new tab)

Other radiology

See the full radiology ranking